( cancer in the developing world will be...)Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research,Health

Eloxatin(R) (oxaliplatin for injection), a DACH platinum, is approved in combination with infusional 5-FU/LV for the second-line treatment of patients with advanced carcinoma of the colon or rectum. In 2004, Eloxatin received additional approval for the first-line treatment of these patients. Based on data showing improvement in disease-free survival, Eloxatin was also approved in 2004 for use in combination with infusional 5-FU/LV in adjuvant (post- surgery) treatment of stage III colon cancer patients.

Clinical Safety Considerations

Eloxatin(R) should be administered under the supervision of a physician experienced in the use of cancer chemotherapeutic agents.

Appropriate management of therapy and complications is possible only when adequate diagnostic and treatment facilities are readily available.

Anaphylactic-like reactions to Eloxatin(R) have been reported and may occur within minutes of Eloxatin(R) administration. Epinephrine, corticosteroids, and antihistamines have been employed to alleviate symptoms, and discontinuation of Eloxatin(R) therapy may be required.

    -- Eloxatin(R) should not be administered to patients with a history of

       known allergy to Eloxatin(R) or other platinum compounds.

       Hypersensitivity and anaphylactic/anaphylactoid reactions to

       Eloxatin(R) have been reported and were similar in nature and severity

       to those reported with other platinum compounds (ie, rash, urticaria,

       erythema, pruritus, and, rarely, bronchospasm and hypotension). These

       reactions occur within minutes of administration and should be managed

       with appropriate supportive therapy. Drug-related deaths from this

       reaction have been reported


    -- Eloxatin(R) may cause fet
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12 
Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral
Anticoagulant, Presented Today at the XXIst Congress of the
International Society on Thrombosis and Haemostasis
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule
Therapeutic Clinical Trial Results Presented at the 34th Annual
Meeting of the Controlled Release Society
3. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at
European Society for Medical Oncology
4. Clinical Data From Nymox BPH Drug To Be Presented at American
Urological Association Meeting
5. The European Myeloma Platform Reports New Survival data for
Revlimid Presented at the International Myeloma Workshop in Greece
6. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data
Presented at International Myeloma Workshop
7. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S.
Urology Meetings
8. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating
MacroVascular Outcomes Presented at the American Diabetes
Association 67th Scientific Sessions
9. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S.
Urology Meetings
10. ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin
Conjugate Data Presented at American Diabetes Association Annual
Meeting
11. New Data Presented on Micardis (Telmisartan) Tablets in
Hypertensive Patients With Type 2 Diabetes